Mitek and Verigen to market cartilage product:
This article was originally published in Clinica
Executive Summary
German company Verigen and Mitek Worldwide, part of Johnson & Johnson subsidiary Ethicon, are to market an advanced articular cartilage repair system in the US and Canada. Mitek, which develops devices for surgical sports medicine and soft tissue repair, will carry out clinical trials and seek marketing approval. Leverkusen-based Verigen is an autologous biotherapy company specialising in tissue engineering. Its R&D efforts are concentrated on products and procedures for addressing diseases of cartilage, bone and connective tissue.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.